A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer

被引：17

作者：

Ambe C. ^{[1
]}

Fulp W. ^{[2
]}

Springett G. ^{[1
]}

Hoffe S. ^{[3
]}

Mahipal A. ^{[1
]}

机构：

[1] Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive FOB-2, Tampa, 33612, FL

[2] Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

[3] Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

来源：

Journal of Gastrointestinal Cancer | 2015年 / 46卷 / 3期

关键词：

Chemotherapy; Meta-analysis; Pancreatic neoplasms; Radiotherapy;

D O I：

10.1007/s12029-015-9734-z

中图分类号：

学科分类号：

摘要：

Objectives: Pancreatic cancer is the fourth most common cause of cancer deaths in the USA. Despite the fact that the radiotherapy in addition to chemotherapy (CT) is frequently employed, the role of chemoradiation therapy (CRT) in the treatment of locally advanced pancreatic cancer (LAPC) remains controversial. We conducted a systemic review and meta-analysis to evaluate the effect of radiation treatment in addition to CT in patients with LAPC. Methods: Only randomized controlled trials that compared CRT to CT and reported time to event summary were included in this study. The primary end point was overall survival expressed as hazard ratio (HR). Due to significant heterogeneity, random-effects model statistics were used. Results: Five eligible studies were included with a total of 593 patients (CT, N = 298; CRT, N = 295). Two studies demonstrated statistically significant difference in OS in favor of CRT and the rest of the studies did not demonstrate any significant differences. Meta-analysis demonstrated that there was a non-significant trend toward a survival benefit in the CRT arm; HR 0.913 (95 % CI 0.595–1.400, p = 0.675). No significant differences in overall results were seen with sensitivity analysis. Conclusions: The addition of radiation therapy to CT in the treatment of LAPC is associated with a non-significant trend toward survival advantage. Larger randomized controlled trials using modern CT regimens and radiation techniques are needed to further clarify the role of radiation in this setting. © 2015, Springer Science+Business Media New York.

引用

页码：284 / 290

页数：6

共 26 条

[1]

Abrams R.A., Winter K.A., Regine W.F., Safran H., Hoffman J.P., Lustig R., Et al., Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704–a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas, Int J Radiat Oncol Biol Phys, 82, pp. 809-816, (2012)

[2]

Bardeesy N., Cheng K.H., Berger J.H., Chu G.C., Pahler J., Olson P., Et al., Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer, Genes Dev, 20, pp. 3130-3146, (2006)

[3]

Berlin J.D., Catalano P., Thomas J.P., Kugler J.W., Haller D.G., Benson A.B., Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297, J Clin Oncol, 20, pp. 3270-3275, (2002)

[4]

Bramhall S.R., Rosemurgy A., Brown P.D., Bowry C., Buckels J.A., Marimastat Pancreatic Cancer Study G., Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial, J Clin Oncol, 19, pp. 3447-3455, (2001)

[5]

Bramhall S.R., Schulz J., Nemunaitis J., Brown P.D., Baillet M., Buckels J.A., A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer, Br J Cancer, 87, pp. 161-167, (2002)

[6]

Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J Clin Oncol, 15, pp. 2403-2413, (1997)

[7]

Chauffert B., Mornex F., Bonnetain F., Rougier P., Mariette C., Bouche O., Et al., Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study, Ann Oncol, 19, pp. 1592-1599, (2008)

[8]

Chuong M.D., Springett G.M., Freilich J.M., Park C.K., Weber J.M., Mellon E.A., Et al., Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated, Int J Radiat Oncol Biol Phys, 86, pp. 516-522, (2013)

[9]

Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 364, pp. 1817-1825, (2011)

[10]

Faris J.E., Blaszkowsky L.S., McDermott S., Guimaraes A.R., Szymonifka J., Huynh M.A., Ferrone C.R., Wargo J.A., Allen J.N., Dias L.E., Kwak E.L., Lillemoe K.D., Thayer S.P., Murphy J.E., Zhu A.X., Sahani D.V., Wo J.Y., Clark J.W., Fernandez-del Castillo C., Ryan D.P., Hong T.S., FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience, Oncologist, 18, pp. 543-548, (2013)

← 1 2 3 →